Search
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commissio...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalOmaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mit...
Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inh...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigationalTazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA app...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProthipendyl
go.drugbank.com/drugs/DB12958InvestigationalProthipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLevosalbutamol
go.drugbank.com/drugs/DB13139ApprovedLevosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salbutamol has been marketed as a racemic mixture, although beta2-agonist...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsClobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions. Topical clobetasone butyr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMiocamycin
go.drugbank.com/drugs/DB13287ApprovedMiocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and m...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsDihydroergocristine
go.drugbank.com/drugs/DB13345ApprovedDihydroergocristine is part of the ergoloid mixture products. It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline. To know more about ergoloid mixtures, please visit ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates